Regeneron Pharmaceuticals REGN reported second-quarter earnings of $6.04 per share, which beat the analyst consensus estimate of $5.37 by 12.48%. This is a 10.83% increase over earnings of $5.45 per share from the same period last year.
The company reported quarterly sales of $1.93 billion, which beat the analyst consensus estimate of $1.8 billion by 7.22%. This is a 20.02% increase over sales of $1.608 billion the same period last year.
"We had a great quarter marked by top- and bottom-line growth as well as important advances across our innovative R&D engine," said Leonard Schleifer, CEO of Regeneron. "We are further unlocking EYLEA's potential to help patients with the recent approval in diabetic retinopathy, and are advancing a high-dose formulation into the clinic later this year.”
Regeneron Pharmaceuticals closed Monday at $299.57. The stock has a 52-week high of $442.00 and a 52-week low of $287.66.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
